Universita Degli Studi Di Messina
- Address
- Via Consolare Valeria 1, 98125 Messina, Italy
Respiratory Tract Diseases
Clinical research at Universita Degli Studi Di Messina includes studies in asthma and other respiratory tract diseases, with attention to both moderate-to-severe controlled asthma and severe eosinophilic asthma. The trials are designed to assess treatment performance and long-term safety while exploring new options that may improve symptom control.
- Severe asthma with an eosinophilic phenotype
- Moderate to severe controlled asthma
- Evaluation of new therapies for asthma management
- Long-term safety and effectiveness of respiratory treatments
This area reflects a strong focus on improving care for chronic airway disease through better disease control and safer treatment strategies.
Digestive System Diseases
The site is also active in digestive system diseases, including research on pediatric bowel cleansing for colonoscopy preparation in children and teenagers with colonic disease. These studies aim to improve diagnostic readiness and support more effective gastrointestinal care in younger patients.
- Colonic disease
- Improving bowel preparation before colonoscopy
- Testing the effectiveness of cleansing approaches in pediatric care
- Supporting better diagnostic outcomes in gastrointestinal research
This line of research highlights practical advances in how digestive conditions are assessed and managed, especially in pediatric populations.
Nutritional and Metabolic Diseases
In nutritional and metabolic diseases, clinical trials at the DAI Materno Infantile are focused on type 1 diabetes and late-onset Pompe disease. The studies are evaluating whether new add-on treatments can help preserve insulin-producing cell function or improve lung function in patients already receiving standard care.
- Diabetes Mellitus, Type 1
- Late-onset Pompe disease
- Preservation of beta-cell function in new-onset diabetes
- Assessing added treatment benefit in metabolic disease
This research aims to expand treatment possibilities for complex chronic disorders by testing therapies that may improve long-term disease control and organ function.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Dr. Falk Pharma GmbH1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita Degli Studi Di Messina
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. | Shionogi B.V. | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ascorbic Acid | 1 | Unknown | 2026-03-24 | 2026-03-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
